Having said that, it is an excellent introductory indication that may help hematologists decide whether or not to use it for sickle cell or beta thalassemia patients in the future. Expanding ...

Thirty-eight participants had homozygous hemoglobin S (Hb SS) genotype, 11 had sickle hemoglobin C (hemoglobin S and ...

β-Thalassemia is a genetic disorder characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to ineffective erythropoiesis and severe anemia. Patients with ...

The landscape began to shift with the approval of the first gene therapy for transfusion-dependent beta thalassemia, Zynteglo, by Bluebird Bio in August 2022. This was followed by the approvals of ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Some people also inherit rarer types of hemoglobin D, E and O. The severity of these rarer types of sickle cell disease varies. — Hemoglobin S–beta-thalassemia: When individuals are diagnosed with ...

Life expectancy for people with sickle cell in the U.S. has increased to about 50 years, but some people with the disease still face stigma and other barriers in health care ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. BYC-103 is under development for the treatment of beta thalassemia.

LEXINGTON, Ky. (WKYT) - WKYT’s blood drive kicks off tomorrow! You’ll be able to give blood at five locations in Central ...